NCT06482489 Accurate Prostate Cancer Following Using Low-Field MRI (Low-PRISM)
| NCT ID | NCT06482489 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Lausanne Hospitals |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 74 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2025-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 74 participants in total. It began in 2024-11-01 with a primary completion date of 2025-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study compares the effectiveness of low-field MRI (0.55T) with high-field MRI (3T) in prostate cancer screening and image quality. It consists of three phases: optimizing the low-field MRI protocol with healthy volunteers, evaluating image quality in patients with metallic artifacts (like hip prostheses), and assessing low-field MRI in patients with suspicious prostate lesions found on high-field MRI.
Eligibility Criteria
Inclusion Criteria: Work Package1 (WP): 0.55T MRI Protocol Development * Healthy male volunteers aged 18 and above. * Agree to be contacted for incidental findings * Signed informed consent WP2: 0.55T Prostate MRI with patients with metallic implant(s) * Adult men (≥18 y.o) with 3T MRI reported as sub-diagnostic due to metallic implants * Signed informed Consent WP3: 0.55T Prostate MRI with patients with suspicious lesion(s) * Adult men (≥18 y.o) * PI-RADS 4/5 lesions detected on 3T MRI, schedules for targeted biopsy * Signed informed consent Exclusion Criteria: WP1: 0.55T MRI Protocol Development * Individuals with a history of prostate cancer * MR Contraindications as listed in the MR Safety Screening form WP2: 0.55T Prostate MRI with patients with metallic implant(s) * Contraindications as per MD instructions * Any condition making the patient unsuitable for the study * Refusal to be notified in case of incidental finding on the examination WP3: 0.55T Prostate MRI with patients with suspicious lesion(s) * Individuals with a history of prostate cancer. * Contraindications as per MD instructions * Any condition making the patient unsuitable for the study * Refusal to be notified in case of incidental finding on the examination
Contact & Investigator
Ileana Jelescu, Prof
STUDY CHAIR
University of Lausanne Hospitals
Frequently Asked Questions
Who can join the NCT06482489 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06482489 currently recruiting?
Yes, NCT06482489 is actively recruiting participants. Contact the research team at Naik-Vietti-Violi@chuv.ch for enrollment information.
Where is the NCT06482489 trial being conducted?
This trial is being conducted at Lausanne, Switzerland.
Who is sponsoring the NCT06482489 clinical trial?
NCT06482489 is sponsored by University of Lausanne Hospitals. The principal investigator is Ileana Jelescu, Prof at University of Lausanne Hospitals. The trial plans to enroll 74 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.